Labopharm files New Drug Submission with Health Canada for novel antidepressant

... was no different from placebo. The overall drop out rate in the study was 25 percent. The drop out rate was 21 percent in the placebo group and 30 ... treatment due to somnolence or sedation. The drop out rate observed in this study is comparable to ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... (Geurts, et al.) scientists used ZFNs to knock out an inserted reporter gene and two native rat ... sequence. Previously, ZFNs were used to knock out specific genes in fruit flies, worms, cultured ... antibody platform, used Sangamo's ZFNs to knock out the gene encoding rat immunoglobulin M (IgM), an ...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

... the comparator arm, the response rate was seven out of 39 patients (18%) with three CRu. The ... patients treated with standard chemotherapy (14 out of 70 patients (20.0%) for the pixantrone arm compared to four out of 70 patients (5.7%) for the standard ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... from the investigator-driven study show that five out of five patients evaluable for responses showed either partial responses to Gleevec (3 out of 5) or stable disease (2 out of 5). Responses in two of the three patients are ...

CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals

... all staff members find the best ways to carry out these goals and identify and eliminate barriers ... of his soiled gloves and gown. The escort figured out that by quickly sliding out of the gown, inverting it, folding it tightly and ...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

... In this study, approximately half (36 out of 74) of the screened patients successfully ... intention-to-treat patients set. Only 1 patient out of 36 (approximately 2.8%) dropped out of the study during the maintenance period for ...

The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs

... to each other by fine threads, you might pull out clumps of them together. Using a novel ... the power of gene discovery studies to ferret out potential targets for disease treatments. In ... team created a pathway-based approach that seeks out interacting or related genes along the same ...

News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments

... health systems in Michigan. To find out more about MRMC, visit ... throughout the McLaren network. To find out more about GLCI, visit http://www.glci.com . ... HMO are also a part of the system. To find out more about how we're changing the future of ...

Battelle Scientists Named on Patent for Making Oxygen From Light and Water

... of the technology. "It adds oxygen and takes out CO2." Astronauts will have plenty of oxygen and ... When miners are trapped or a submarine runs out of breathable air, PDEC products could one day ... keep them alive by providing oxygen and scrubbing out carbon dioxide. Battelle scientists predict ...

Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu

... about flu vaccine options. Overall, about two out of three parents (67 percent) surveyed say ... without having to get a shot, and about three out of four school-age children (77 percent) say the ... their child vaccinated against the flu, nearly 4 out of 5 (78 percent) say they would be extremely or ...

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

... compounds. The collaboration, which is spelt out in a Memorandum of Understanding (MOU) that was ... Executive Officer, Dr. Lim Suet Wun says, "165 out of 1,069 ongoing research studies in NHG focus ... of cancer. Our large base has allowed us to carry out meaningful and effective clinical trials." ...

New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option

... about ongoing and planned PrEP research, and lays out an agenda for action on key issues that must be ... in some populations and is being rolled out in some African countries. "Although still ... now. This plan should address the issues set out in a Lancet paper of July 2007, which called ...

More Than 300 New Medicines Being Developed for Mental Illnesses

... know that there are many new, potential options out there that could allow them a better quality ... thinks they may have a mental illness -- to find out what the options are and seek treatment. People ... from the public, Pantoliano has chosen to speak out about his disease, and founded the organization ...

New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)

... (< 120/80 mm Hg) (placebo:1.4%). - Eight out of 10 (cumulative 81%) patients with stage 1 ... BENICAR HCT (placebo: 43.1%). - Six out of 10 (cumulative 60.3%) patients with stage 1 ... demonstrated in a sub analysis that eight out of ten (cumulative 81%) patients with stage 1 ...

White Nose Syndrome: Is Pennsylvania Next?

... and the U.S. Fish and Wildlife Service to sort out what is killing bats in New York and New ... now and it doesn't look like we're going to find out anytime soon. Nothing like this has been ... sources of additional funding to help states sort out what's happening within their borders. It also ...

STAR Cranial Centers of Excellence Offer Cutting-Edge Treatment to Dallas Area Children

... were worth it. "People told me to wait it out because they thought Christian's head would grow ... cute. I was not embarrassed." Aguilar pointed out that the helmet had an unexpected benefit for ... Reed said. "Zoe did great. After she was out of the helmet, I realize that we did spend a lot ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... study provided encouragement to carry out a Phase III trial. The criteria for going forward ... earlier Phase I study in eight patients carried out at New York-Presbyterian/Weill Cornell that was ... in the study it was preserved or improved in 10 out of 13 patients after six months of GAMMAGARD S/D ...

Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders

... which often are unpleasant and violent. Acting out is caused by a loss of normal muscle paralysis in ... There are very few studies that have been carried out on RBD on a large scale. Plus, we currently ... Boeve and a team of Mayo Clinic physicians set out to determine whether cognitively-normal ...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease

... based on Hebrew University technologies licensed out by Yissum. Ranked among the top ... 5500 patents covering 1600 inventions; licensed out 480 technologies and spun out 65 companies. Yissum's business partners span the ...

Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation

... in the way clinical trials are designed, carried out and funded in the U.S. with serious implications ... goal of human studies, the EDICT review singles out the under-representation of women, older people, ... of age. Older Americans are also routinely left out of clinical trials studying diseases associated ...

Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines

... development. This work, which was carried out in collaboration with scientists from Pfizer Inc, ... Unit. "In addition to reagents for knocking out an investigator's 'favorite gene' in a particular ... we have used these same techniques for knocking out genes in multiple crop plants and to develop ZFP ...

Nobel Prize-Winning Discovery

... stem cells can be inherited. Want to figure out what role a certain gene plays in susceptibility ... disorder devastates multiple organ systems in one out of every 3,700 babies born in the United States, ... functions. Eventually, this could mean knocking out cystic fibrosis and other inherited disorders. ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... bortezomib dose 2 times per week every 2 weeks out of 3 weeks. A total of 71 patients were ... and minor responses) was 47% (9 out of 19 evaluable patients), including 2 complete ... the tanespimycin injection (45%, 5 out of 11 patients; 2 CR, 1 PR, 2 MR) and the ...

Interview of the Vice President

... a Speaker who, from my perspective, is that far out of the sort of mainstream -- she is a ... attacks as a law enforcement problem. We went out and arrested the bad guy, put him on trial, ... attacks on the World Trade Center is doing life out in Colorado. That was the old way of looking at ...

Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS

... which promoted awareness of HIV/AIDS. Reach out and Read Bristol-Myers Squibb also joined with ... of New Jersey (HINJ), in supporting Reach out and Read programs at various New Jersey ... children's literacy program modeled on the Reach out and Read program at one of its ...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... assess the volume of air that can be moved in and out of the lungs. The three parameters which will be ... 1 (FEV1), the volume of air that can be breathed out during the first second of forced exhalation; ... of air that can be breathed in after breathing out normally. Blood cells and cytokines will also be ...

FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis

... that glucocorticoids are used by up to three out of every 100 adults (3 percent) over age 50,(3) ... patient receiving teriparatide (0.6 percent; 1 out of 171 patients) and 10 patients receiving alendronate (6.1 percent; 10 out of 165 patients) had greater than or equal ...

Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial

... as evidenced by clinical trial data now reporting out to five years," said Paul LaViolette, Chief ... preventing restenosis, or additional procedures, out to five years across a wide variety of patients ... offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

... thrombosis rates between XIENCE V and TAXUS out to one year. "To date, XIENCE V is the only ... rates of stent thrombosis for XIENCE V or TAXUS out to one year in the SPIRIT III trial. Rates of ... event at one year and no additional MACE events out to three years. In addition, the number of late ...

38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty

... of the Millennium Development Goals. They spoke out to demand a more urgent political response to the ... the Occupied West Bank and Gaza spoke out saying no to poverty. The activities organized ... human chain. -- Faith leaders Stand Up and Speak out -- At papal mass at the Vatican Pope Benedict ...

New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments

... Branch. "We now are faced with trying to figure out how this variant of STAT4 increases a person's ... of volunteers, we will have more power to pull out additional new genes and figure out what they do in triggering these diseases. ...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

... bortezomib dose 2 times per week every 2 weeks out of 3 weeks). Of these 56 patients, all had ... responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the 18 responding patients (44%), 8 out of 14 patients were bortezomib-nave (57%); ...

Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006

... and then just stopped, but it could have gotten out of control. The world really may have dodged a ... and other public-health officials, to carry that out efficiently," Halloran said. "The manuals on how ... said. If a smoldering disease cluster does flame out of control, the software also could be used to ...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... bortezomib dose 2 times per week every 2 weeks out of 3 weeks). Of these 56 patients, all had ... responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the ... of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated ...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... study, 2 ml of RK-023 preparation was applied to the vertex region of 6 out of 9 healthy adult males and a placebo to that of the remaining 3 ... night 2 ml of RK-023 preparation or 2 ml of placebo was applied to 6 and 2 out of 8 healthy adult males respectively. No serious adverse event was ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... your risk of developing Alzheimer's disease or another dementia. Find out more by visiting the Alzheimer's Association at www.alz.org. ... a Clinical Studies Initiative to begin to address this problem. Find out more at 1-800-272-3900 or www.alz.org. About ICAD 2009 ...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

... a minimum re-dosing interval of 20 minutes. Patients were allowed to drop out of the study at any time. The primary efficacy endpoint was SPID-12 (a ... carried forward). Additionally, the proportion of patients who dropped out due to inadequate analgesia, a clinically meaningful secondary endpoint, ...

China Animal Welfare Law Under Review While 36,000 Dogs Culled

... a death toll of 36,000. Claiming rabies outbreak, the city has sent out dog-beating squads to kill any animal spotted on the street, stray or ... welfare organizations, IFAW has representation in 16 countries and carries out its animal welfare work in more than 40. IFAW works from its global ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells. The poster presentation gave an update of ... treatment with single agent blinatumomab(2). The data show that 11 out of 12 patients having received a dose of 0.06 mg/m(2) per day during the ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... - Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III ... lymphoid tissue, lymph vessels and lymph fluid that help the body filter out bacteria and fight disease. Since lymphatic tissue is located throughout ...